1. Home
  2. BEAM vs VRE Comparison

BEAM vs VRE Comparison

Compare BEAM & VRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BEAM
  • VRE
  • Stock Information
  • Founded
  • BEAM 2017
  • VRE 1949
  • Country
  • BEAM United States
  • VRE United States
  • Employees
  • BEAM N/A
  • VRE N/A
  • Industry
  • BEAM Biotechnology: Biological Products (No Diagnostic Substances)
  • VRE Real Estate Investment Trusts
  • Sector
  • BEAM Health Care
  • VRE Real Estate
  • Exchange
  • BEAM Nasdaq
  • VRE Nasdaq
  • Market Cap
  • BEAM 1.8B
  • VRE 1.6B
  • IPO Year
  • BEAM 2020
  • VRE 1994
  • Fundamental
  • Price
  • BEAM $16.19
  • VRE $15.06
  • Analyst Decision
  • BEAM Strong Buy
  • VRE Buy
  • Analyst Count
  • BEAM 11
  • VRE 4
  • Target Price
  • BEAM $48.90
  • VRE $18.50
  • AVG Volume (30 Days)
  • BEAM 1.9M
  • VRE 466.0K
  • Earning Date
  • BEAM 05-06-2025
  • VRE 07-23-2025
  • Dividend Yield
  • BEAM N/A
  • VRE 2.10%
  • EPS Growth
  • BEAM N/A
  • VRE N/A
  • EPS
  • BEAM N/A
  • VRE N/A
  • Revenue
  • BEAM $63,578,000.00
  • VRE $279,630,000.00
  • Revenue This Year
  • BEAM N/A
  • VRE $0.12
  • Revenue Next Year
  • BEAM $10.59
  • VRE $2.42
  • P/E Ratio
  • BEAM N/A
  • VRE N/A
  • Revenue Growth
  • BEAM N/A
  • VRE 3.92
  • 52 Week Low
  • BEAM $13.53
  • VRE $13.84
  • 52 Week High
  • BEAM $35.25
  • VRE $18.85
  • Technical
  • Relative Strength Index (RSI)
  • BEAM 39.35
  • VRE 44.12
  • Support Level
  • BEAM $15.35
  • VRE $14.81
  • Resistance Level
  • BEAM $17.47
  • VRE $15.29
  • Average True Range (ATR)
  • BEAM 0.90
  • VRE 0.30
  • MACD
  • BEAM -0.07
  • VRE -0.00
  • Stochastic Oscillator
  • BEAM 24.71
  • VRE 49.56

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

About VRE Veris Residential Inc.

Veris Residential Inc is a fully-integrated, self-administered and self-managed real estate investment trust (REIT). The company owns and operates a real estate portfolio comprised predominantly of multifamily rental properties located mainly in the Northeast and Class A office properties. The company performs substantially all real estate management, leasing, acquisition and development on an in-house basis. The properties are in three states in the Northeast, plus the District of Columbia. The company operates in two industry segments multifamily real estate & services and commercial & other real estate. The majority of revenue is from Multifamily real estate services.

Share on Social Networks: